Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verastem, Inc. - Common Stock (NQ:VSTM)

6.530 -0.480 (-6.85%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Verastem, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
AI Boom Wanes In June: Nvidia Falls Under $1T As Benzinga Reviews May's Champions
Via Benzinga
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029
EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END 
Via FinancialNewsMedia
Verastem Oncology Announces Reverse Stock Split
From Verastem Oncology
Via Business Wire
Verastem: Q1 Earnings Insights
Via Benzinga
Analyst Initiates Verastem With Neutral While 'Waiting For FDA Go-Ahead'
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Hibbett Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Onfolio Holdings, Inc. (NASDAQ: ONFO) gained 73% to $2.02 after the company announced it completed development of a generative AI search tool. 
Via Benzinga
Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib
From Verastem Oncology
Via Business Wire
Verastem Oncology Appoints Karin Tollefson, PhD, to Board of Directors
From Verastem Oncology
Via Business Wire
Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
From Verastem Oncology
Via Business Wire
Verastem Oncology to Participate in Upcoming Investor Conferences
From Verastem Oncology
Via Business Wire
New Data from Interim Analysis of Verastem Oncology’s RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society of Clinical Oncology Annual Meeting
From Verastem Oncology
Via Business Wire
Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days
From Verastem Oncology
Via Business Wire
7 Very Undervalued Penny Stocks to Buy in April 2023
Undervalued penny stocks present investors who are very bullish on the near-term future with a high-risk, high-reward option. 
Via InvestorPlace
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023
Via Benzinga
New Verastem Oncology Initiative, Let’s Talk About LGSOC, Calls Attention to Rare Form of Ovarian Cancer
From Verastem Oncology
Via Business Wire
Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
From Verastem Oncology
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Why Smith Micro Software Shares Are Trading Lower By Over 46%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Lucira Health, Inc. (NASDAQ: LHDX) jumped 354% to $0.6369 after the company announced FDA authorization for its at-home combination COVID-19 & flu test. 
Via Benzinga
Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
Verastem Oncology Appoints Rob Gagnon to Board of Directors
From Verastem Oncology
Via Business Wire
Cigna To Rally 15%? Plus Needham Slashes PT On This Stock By 40%
Raymond James raised the price target on Cigna Corporation (NYSE: CI) from $330 to $370. Raymond James analyst John Ransom maintained a Strong Buy rating on the stock. Cigna shares rose 0.1% to $322.17... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Cidara Therapeutics (NASDAQ:CDTX) shares rose 14.6% to $0.64 during Monday's pre-market session. The market value of their outstanding shares is at $44.9 million. The company's, Q3 earnings... 
Via Benzinga
Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
From Verastem Oncology
Via Business Wire
10 Best Medical Stocks Under $5
The medical industry is one of the most lucrative sectors globally, and it is one that sees the highest spending in terms of research and development, and breakthrough advances through keeping up the... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.